Li XY - Search Results

1

Front-line Therapy in Advanced Non-Small Cell Lung Cancer With Sensitive Epidermal Growth Factor Receptor Mutations: A Network Meta-analysis.

Li XY, Lin JZ, Yu SH. Li XY, et al. Clin Ther. 2020 Feb;42(2):338-350.e4. doi: 10.1016/j.clinthera.2019.12.006. Epub 2020 Jan 11. Clin Ther. 2020. PMID: 31937461

2

Maintenance treatment with different strategies in advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Cai H, Lin Y, Li W, Li X. Cai H, et al. Clin Lung Cancer. 2013 Jul;14(4):333-41. doi: 10.1016/j.cllc.2012.10.010. Epub 2012 Dec 29. Clin Lung Cancer. 2013. PMID: 23276822

3

Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials.

Li X, Wang H, Lin W, Xu Q. Li X, et al. Curr Med Res Opin. 2014 Nov;30(11):2295-304. doi: 10.1185/03007995.2014.909392. Epub 2014 Apr 30. Curr Med Res Opin. 2014. PMID: 24701984 Review.

4

Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials.

Li X, Zhu S, Hong C, Cai H. Li X, et al. Curr Med Res Opin. 2016;32(3):555-62. doi: 10.1185/03007995.2015.1131152. Epub 2016 Jan 13. Curr Med Res Opin. 2016. PMID: 26652645

5

Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials.

Yu S, Xu Q, Yuan Y, Li X, Cai H. Yu S, et al. Curr Med Res Opin. 2016 Dec;32(12):1927-1934. doi: 10.1080/03007995.2016.1219709. Epub 2016 Sep 1. Curr Med Res Opin. 2016. PMID: 27479336

6

Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials.

Lin WZ, Xu QN, Wang HB, Li XY. Lin WZ, et al. Among authors: li xy. Breast Cancer. 2017 May;24(3):345-352. doi: 10.1007/s12282-017-0770-3. Epub 2017 Mar 21. Breast Cancer. 2017. PMID: 28324247 Review.

7

A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?

Lin JZ, Ma SK, Wu SX, Yu SH, Li XY. Lin JZ, et al. Among authors: li xy. Medicine (Baltimore). 2018 Jul;97(30):e11569. doi: 10.1097/MD.0000000000011569. Medicine (Baltimore). 2018. PMID: 30045282 Free PMC article.

8

CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.

Huang HW, Huang LS, Xu QN, Wang HB, Li XY, Lin JZ. Huang HW, et al. Among authors: li xy. Medicine (Baltimore). 2019 Jan;98(1):e13909. doi: 10.1097/MD.0000000000013909. Medicine (Baltimore). 2019. PMID: 30608416 Free PMC article.

9

First-line checkpoint inhibitors for wild-type advanced non-small-cell cancer: a pair-wise and network meta-analysis.

Wang XJ, Lin JZ, Yu SH, Wu SX, Luo HS, Du ZS, Li XY. Wang XJ, et al. Among authors: li xy. Immunotherapy. 2019 Mar;11(4):311-320. doi: 10.2217/imt-2018-0107. Immunotherapy. 2019. PMID: 30678553

10

Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response.

Weng ZJ, Wu SX, Luo HS, Du ZS, Li XY, Lin JZ. Weng ZJ, et al. Among authors: li xy. Inquiry. 2021 Jan-Dec;58:469580211056213. doi: 10.1177/00469580211056213. Inquiry. 2021. PMID: 34806458 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,798 results

Search Page

Filters